The Latest Cardiac and Vascular News
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its […]
THOUSAND OAKS, Calif., Nov. 3, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include: Total revenues decreased 1% to $6.7 billion in comparison to the third quarter of 2021, resulting from a 1% decline in global product sales, which reflected 8% volume growth offset primarily […]
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND OAKS, Calif., Aug. 29, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented new […]
THOUSAND OAKS, Calif., Aug. 4, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2021, resulting from 3% growth in global product sales partially offset by lower Other Revenue from our […]
Study Showed Significant, Sustained Reduction in Lipoprotein(a) During Treatment Period Lipoprotein(a) Reduction was Consistent With Phase 1 Results THOUSAND OAKS, Calif., May 31, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or […]
Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After Completing the Phase 3 FOURIER Trial Repatha is the Longest Studied PCSK9i THOUSAND OAKS, Calif., April 27, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) […]
THOUSAND OAKS, Calif., Feb. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include: For the fourth quarter, total revenues increased 3% to $6.8 billion in comparison to the fourth quarter of 2020, driven by increased Other Revenue […]
THOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021. Key results include: Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 4% globally, […]
Final Analysis From Open-Label Extension Study in Patients with Human Immunodeficiency Virus and Dyslipidemia THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) open label extension trial of patients living with HIV who have high cholesterol, […]
Breakthrough Multicentered Study will Evaluate Efficacy of Digital Health Data Collection Outside the Clinic for Guideline-Directed Heart Failure Therapy NEW YORK, April 13, 2021 /PRNewswire/ — Datos Health, a leader in remote care automation, today announced its collaboration with Amgen, one of the world’s leading independent biotechnology companies, on a new study to evaluate […]
